Lista de obras -

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

scholarly article

A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation.

artículo científico publicado en 2019

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

scientific article published on 31 August 2016

A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors

artículo científico publicado en 2014

A historical appreciation of bronchopulmonary neuroendocrine neoplasia: resolution of a carcinoid conundrum

artículo científico publicado en 2014

A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis

artículo científico publicado en 2017

A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm

scientific article published on 20 June 2020

A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.

artículo científico publicado en 2014

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

artículo científico publicado en 2018

An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis

artículo científico publicado en 2019

Author Correction: Radiopharmaceutical therapy in cancer: clinical advances and challenges

artículo científico publicado en 2020

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study

artículo científico publicado en 2014

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

artículo científico publicado en 2010

Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

artículo científico publicado en 2019

Blood mRNA Measurement (NETest) for Neuroendocrine Tumors diagnosis of Image-negative liver metastatic disease

scientific article published on 01 March 2019

Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.

artículo científico publicado en 2015

Blood transcript analysis and metastatic recurrent small bowel carcinoid management

artículo científico publicado en 2014

CURRENT CONCEPTS IN (68)Ga-DOTATATE NEN IMAGING: INTERPRETATION, BIODISTRIBUTION, DOSIMETRY AND MOLECULAR STRATEGIES.

artículo científico publicado en 2017

Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus

artículo científico publicado en 2019

Chromogranin A: any relevance in neuroendocrine tumors?

artículo científico publicado en 2015

Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.

artículo científico publicado en 2015

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

article

Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.

artículo científico publicado en 2015

Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.

artículo científico publicado en 2006

Dosimetry in Peptide radionuclide receptor therapy: a review.

artículo científico publicado en 2006

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

artículo científico publicado en 2017

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.

artículo científico publicado en 2018

EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

artículo científico publicado en 2011

EANM procedure guideline for treatment of refractory metastatic bone pain

scientific article published on 01 October 2008

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

article

Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

artículo científico publicado en 2017

Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl

artículo científico publicado en 2002

Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC

artículo científico publicado en 2015

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

artículo científico publicado en 2020

In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas

artículo científico publicado en 2003

Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

artículo científico publicado en 2005

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

artículo científico publicado en 2020

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

artículo científico publicado en 2008

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

artículo científico publicado en 2016

Long-term results of PRRT in advanced bronchopulmonary carcinoid

artículo científico publicado en 2015

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

artículo científico publicado en 2014

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.

artículo científico publicado en 2009

Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy

artículo científico publicado en 2020

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

artículo científico publicado en 2020

Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms

artículo científico publicado en 2017

Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal

artículo científico publicado en 2008

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

scholarly article by Lisa Bodei et al published August 2016 in Endocrine-related cancer

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

artículo científico publicado en 2020

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

scientific article published on 17 January 2019

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

article published in 2019

Neuroendocrine neoplasms of the small bowel and pancreas

artículo científico publicado en 2019

Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

artículo científico publicado en 2016

Neuroendocrine tumor biomarkers: current status and perspectives.

artículo científico publicado en 2014

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

artículo científico publicado en 2005

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

artículo científico publicado en 2018

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

artículo científico publicado en 2019

PRRT: Defining the paradigm shift to achieve standardization and individualization

artículo científico publicado en 2014

Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?

artículo científico publicado en 2020

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

artículo científico

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors

artículo científico publicado en 2014

Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma

artículo científico publicado en 2009

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

artículo científico publicado en 2011

Planning combined treatments of external beam radiation therapy and molecular radiotherapy

artículo científico

Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective

artículo científico publicado en 2014

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

artículo científico publicado en 2004

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

artículo científico publicado en 2016

Radiopharmaceutical therapy in cancer: clinical advances and challenges

artículo científico publicado en 2020

Receptor radionuclide therapy of tumors: a road from basic research to clinical applications

artículo científico publicado en 2006

Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.

artículo científico publicado en 2004

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

artículo científico publicado en 2004

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

artículo científico publicado en 2002

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

artículo científico publicado en 2002

Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.

artículo científico publicado en 2016

Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach

artículo científico publicado en 2013

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

artículo científico publicado en 2013

Somatostatin Receptor 2-Targeting Compounds

artículo científico publicado en 2017

Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists

artículo científico publicado en 2018

Something more than estimating renal dosimetry

artículo científico publicado en 2010

The Future of Nuclear Medicine, Molecular Imaging, and Theranostics

artículo científico publicado en 2020

The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field

scientific article published in 2022

The NETest: The Clinical Utility of Multigene Blood Analysis in the Diagnosis and Management of Neuroendocrine Tumors

scientific article published on 01 September 2018

The Path to the Future: Education of Nuclear Medicine Therapeutic Specialists as Responsible Physicians

artículo científico publicado en 2019

The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors

artículo científico publicado en 2019

The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever....

artículo científico publicado en 2014

The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors.

artículo científico publicado en 2017

The status of neuroendocrine tumor imaging: from darkness to light?

artículo científico publicado en 2014

The use of Deep Learning and Neural Networks in Imaging - Welcome to the new Mathematical Milieu of Medicine

scientific article published on 07 November 2019

The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progression

artículo científico publicado en 2017

Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations.

artículo científico publicado en 2015

Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review

artículo científico publicado en 2008

Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors

artículo científico publicado en 2013

Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms

scientific article published on 28 August 2018

Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms(PanNENs)

article

Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis

artículo científico publicado en 2019

Whither peptide receptor radionuclide therapy for neuroendocrine tumors: an Einsteinian view of the facts and myths

article

Yttrium-based therapy for neuroendocrine tumors.

artículo científico

Yttrium-labelled peptides for therapy of NET.

artículo científico

Lista de obras de

68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors

A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation.

A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management

A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors

A historical appreciation of bronchopulmonary neuroendocrine neoplasia: resolution of a carcinoid conundrum

A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis

A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm

A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis

Author Correction: Radiopharmaceutical therapy in cancer: clinical advances and challenges

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study

Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas

Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.

Blood mRNA Measurement (NETest) for Neuroendocrine Tumors diagnosis of Image-negative liver metastatic disease

Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.

Blood transcript analysis and metastatic recurrent small bowel carcinoid management

CURRENT CONCEPTS IN (68)Ga-DOTATATE NEN IMAGING: INTERPRETATION, BIODISTRIBUTION, DOSIMETRY AND MOLECULAR STRATEGIES.

Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus

Chromogranin A: any relevance in neuroendocrine tumors?

Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.

Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.

Dosimetry in Peptide radionuclide receptor therapy: a review.

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.

EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds

EANM procedure guideline for treatment of refractory metastatic bone pain

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl

Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC

Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas

Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE.

Long-term results of PRRT in advanced bronchopulmonary carcinoid

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors

Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC.

Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy

Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy

Molecular strategies in the management of bronchopulmonary and thymic neuroendocrine neoplasms

Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal

Myeloid neoplasms after chemotherapy and PRRT: myth and reality

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy

NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease

NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging

Neuroendocrine neoplasms of the small bowel and pancreas

Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms

Neuroendocrine tumor biomarkers: current status and perspectives.

Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.

PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy.

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest

PRRT: Defining the paradigm shift to achieve standardization and individualization

Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?

Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors

Peptide receptor radionuclide therapy for advanced neuroendocrine tumors

Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

Planning combined treatments of external beam radiation therapy and molecular radiotherapy

Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective

Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?

Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer

Radiopharmaceutical therapy in cancer: clinical advances and challenges

Receptor radionuclide therapy of tumors: a road from basic research to clinical applications

Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.

Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: the experience of the European Institute of Oncology Group

Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.

Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach

Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours.

Somatostatin Receptor 2-Targeting Compounds

Somatostatin Receptor Imaging of Neuroendocrine Tumors: From Agonists to Antagonists

Something more than estimating renal dosimetry

The Future of Nuclear Medicine, Molecular Imaging, and Theranostics